Some evidence that acyclovir is effective for treating primary herpetic gingivostomatitis

**Clinical question**  How effective is acyclovir for treating primary herpetic gingivostomatitis (PHG)?

**Bottom line**  One trial (n=72) provided some limited evidence to suggest for children under 6 years of age with PHG acyclovir is effective in reducing the number of oral lesions (NNT* 2), preventing the development of new extraroral lesions (NNT 3), decreasing the difficulty experienced in eating (NNT 3) and drinking (NNT 5) and reducing admissions to hospital (NNT 12). * NNT = number needed to treat to benefit 1 individual.

**Caveat**  Only 2 trials, one with 72 participants and the other with 20 participants, were included in this review. The second study failed to report several methodological items and was inconsistent in its reporting of the outcomes measured.

**Context**  PHG is a highly contagious infection of the oral cavity which is caused by the herpes simplex virus. Only about 5-10% of patients initially infected with the virus develop clinical lesions. It is prevalent in children and adolescents and sometimes can cause uncomfortable symptoms including eating and drinking difficulties and, rarely, life threatening encephalitis.


PEARLS 120, October 2008, written by Brian R McAvoy

[References]

PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They are funded by the New Zealand Guidelines Group.

PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement in the management of individual cases.

View PEARLS online at:
* www.cochraneprimarycare.org